logo

For the Inventor, By the Inventor

Fujian, China

Xu Yan

This inventor holds 3 USPTO granted patents. Top assignees: Xiamen Nuokangde Biological Technology Co., Ltd., Other. Active years: 2021-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xu Yan. Retrieved from https://idiyas.com/inventor/xu-yan-twv4h7le

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3

% Patents Active = 100.0

Average Co-Inventor Count = 3.2

ph-index = 1


Location History:

  • Fujian, CN (2021 - 2022)
  • Guangzhou, CN (2022)

Company Filing History:

goldMedal3 out of 3 
 
Xiamen Nuokangde Biological Technology Co., Ltd.
 patents
silverMedal1 out of 834,570 
Other
 patents
where one patent can have more than one assignee

Years Active: 2021-2022

Loading Chart...
3 patents (USPTO):Explore Patents
1. 11433087 - Anti-tumor compound with high CD169 affinity, method thereof, and use thereof (2022-09-06),
2. 11286238 - Melatonin derivatives, method thereof, and use thereof (2022-03-29),
3. 11033562 - Carbohydrate derivatives used for surface modification of immune cells, use thereof and method thereof (2021-06-15),

Title: Xu Yan: Innovator in Anti-Tumor Compounds and Melatonin Derivatives

Introduction

Xu Yan is a prominent inventor based in Fujian, China. He has made significant contributions to the field of biomedical research, particularly in the development of anti-tumor compounds and melatonin derivatives. With a total of 3 patents to his name, his work has the potential to impact cancer treatment and therapeutic applications.

Latest Patents

Xu Yan's latest patents include an innovative anti-tumor compound with high CD169 affinity. This compound, known as TCC-Neu5A, exhibits specific and broad-spectrum tumor-killing characteristics. It targets tumor cells in vivo and metabolizes onto the surface of these cells to form CD169 ligands. This mechanism allows CD169-positive macrophages to recognize and phagocytize the tumor cells, subsequently releasing tumor-related antigens and triggering an anti-tumor immune response. The compound is effective against various tumors and has shown an inhibitory effect on tumor metastasis. Notably, TCC-Neu5A can be administered both via injection and orally, with low cytotoxicity and animal toxicity.

Another significant patent by Xu Yan involves melatonin derivatives. The disclosed method includes dissolving melatonin in a solvent, adding a catalyst, and conducting a series of reactions to obtain the desired derivatives. This innovative approach opens new avenues for the use of melatonin in therapeutic applications.

Career Highlights

Xu Yan has worked with Xiamen Nuokangde Biological Technology Co., Ltd., where he has contributed to various research projects. His expertise in developing novel compounds has positioned him as a key figure in the field of biomedical innovation.

Collaborations

Some of Xu Yan's notable coworkers include Zhu Li and Yufei Li. Their collaborative efforts have further advanced the research and development of innovative compounds.

Conclusion

Xu Yan's contributions to the field of biomedical research, particularly through his patents on anti-tumor compounds and melatonin derivatives, highlight his role as an influential inventor. His work not only addresses critical challenges in cancer treatment but also paves the way for future innovations in therapeutic applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…